Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors

T. Pokrivcak, R. Lakomy, T. Kazda, A. Poprach, P. Fabian, I. Kiss

. 2021 ; 100 (24) : e26381. [pub] 2021Jun18

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018448

Grantová podpora
MMCI, 00209805 Ministerstvo Zdravotnictví Ceské Republiky

RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018448
003      
CZ-PrNML
005      
20210830100028.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MD.0000000000026381 $2 doi
035    __
$a (PubMed)34128899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pokrivcak, Tomas $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5
245    14
$a The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors / $c T. Pokrivcak, R. Lakomy, T. Kazda, A. Poprach, P. Fabian, I. Kiss
520    9_
$a RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bleomycin $x škodlivé účinky $x terapeutické užití $7 D001761
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a cisplatina $x škodlivé účinky $x terapeutické užití $7 D002945
650    _2
$a etoposid $x škodlivé účinky $x terapeutické užití $7 D005047
650    _2
$a lidé $7 D006801
650    12
$a transplantace ledvin $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a germinální a embryonální nádory $x komplikace $x farmakoterapie $x chirurgie $7 D009373
650    _2
$a orchiektomie $7 D009919
650    _2
$a chronická renální insuficience $x komplikace $x imunologie $x chirurgie $7 D051436
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a testikulární nádory $x komplikace $x farmakoterapie $x chirurgie $7 D013736
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5
700    1_
$a Fabian, Pavel $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5 $u Department of Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5
773    0_
$w MED00012436 $t Medicine $x 1536-5964 $g Roč. 100, č. 24 (2021), s. e26381
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34128899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100028 $b ABA008
999    __
$a ok $b bmc $g 1689526 $s 1138892
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 100 $c 24 $d e26381 $e 2021Jun18 $i 1536-5964 $m Medicine $n Medicine $x MED00012436
GRA    __
$a MMCI, 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace